Home > News > Industry > Pharma News > GSK Pharma net profit...

GSK Pharma net profit falls 3.9 percent to Rs 150.3 crore in Q3

By - Ruchika Sharma
Published On 2022-02-08 04:00 GMT   |   Update On 2022-02-08 11:38 GMT

New Delhi: GlaxoSmithKline Pharmaceuticals Ltd on Monday reported a 3.93 per cent decline in consolidated net profit to Rs 150.35 crore in the third quarter ended December 31, 2021. The company had posted a consolidated net profit of Rs 156.51 crore in the corresponding quarter last fiscal, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.Total income in October-December 2021 stood...

Login or Register to read the full article
Register Now

New Delhi: GlaxoSmithKline Pharmaceuticals Ltd on Monday reported a 3.93 per cent decline in consolidated net profit to Rs 150.35 crore in the third quarter ended December 31, 2021. The company had posted a consolidated net profit of Rs 156.51 crore in the corresponding quarter last fiscal, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

Total income in October-December 2021 stood at Rs 826.24 crore as compared with Rs 805.89 crore in the year-ago period, it added.
Its total expenses were higher at Rs 636.56 crore in the third quarter, compared with Rs 629.69 crore in the year-ago period.
GlaxoSmithKline Pharmaceuticals Managing Director Sridhar Venkatesh said, "GSK's established pharma portfolio recorded strong double-digit growth, driven by our core legacy brands such as Calpol, Augmentin and Ceftum."
While the promoted brands grew, the vaccines business was impacted on account of the third wave of the pandemic, he added. 
"However, as this phase of the pandemic recedes and schools open up across the country, we are witnessing a steady uptake in vaccination.
"We also continue to invest in our brands and raise awareness amongst parents about more innovative vaccines from our portfolio," Venkatesh said.
During the quarter, the company concluded the sale of its Vemgal plant in Karnataka, he said.
He added that "in the subsequent quarters, we will also aim to close the transfer of Iodex and Ostocalcium brands to GlaxoSmithKline Asia Pvt Ltd, as part of GSK plc's plans to create two world-class companies in pharmaceuticals and consumer healthcare".
Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Boehringer Ingelheim Spevigo injection for generalized pustular psoriasis flares gets CDSCO nod
Zydus Lifesciences appoints Shelina Parikh as Additional Director, Independent Director
Zydus Lifesciences arm, MSN Labs collaborate to license, supply cancer drug Cabozantinib in US
Dr Reddy's Labs gets 2 USFDA observations for Duvvada facilities
SII makes strategic investment in IntegriMedical, India's First Needle-Free Injection System Technology
ICMR invites EoI for joint development, commercialization of Salmonella vaccine
USFDA successfully completes inspection at Indoco API Kilo Lab facility, IAS division with no observations
Lupin bags USFDA nod for Midostaurin Capsules for Leukemia treatment